Vascular Parkinsonism

Vascular Parkinsonism

Introduction

Vascular parkinsonism (VP), also known as arteriosclerotic parkinsonism, is a neurodegenerative movement disorder characterized by parkinsonian features resulting from cerebrovascular disease, primarily affecting the basal ganglia and white matter. It accounts for approximately 3-6% of all parkinsonism cases and represents a distinct clinical entity from idiopathic Parkinson's disease[@critchley1929][@zijlmans2003].

VP was first described in detail in the early 20th century, with Critchley popularizing the concept of "arteriosclerotic parkinsonism" in 1929. The condition is now recognized as one of the atypical parkinsonian disorders, with distinct clinical features, imaging findings, and treatment responses compared to Parkinson's disease[@tolosa2006].

Epidemiology

• Prevalence: 3-6% of all parkinsonism cases (approximately 0.5-1 per 100,000)
• Age of onset: Typically >65 years
• Sex ratio: Male predominance (1.5-2:1)
• Risk factors: Hypertension, diabetes, hyperlipidemia, smoking, prior stroke/transient ischemic attack[@reich2010]

Etiology and Pathophysiology

Vascular Lesions

VP results from ischemic or hemorrhagic lesions affecting multiple brain regions[@korczyn2015]:

...

Vascular Parkinsonism

Introduction

Vascular parkinsonism (VP), also known as arteriosclerotic parkinsonism, is a neurodegenerative movement disorder characterized by parkinsonian features resulting from cerebrovascular disease, primarily affecting the basal ganglia and white matter. It accounts for approximately 3-6% of all parkinsonism cases and represents a distinct clinical entity from idiopathic Parkinson's disease[@critchley1929][@zijlmans2003].

VP was first described in detail in the early 20th century, with Critchley popularizing the concept of "arteriosclerotic parkinsonism" in 1929. The condition is now recognized as one of the atypical parkinsonian disorders, with distinct clinical features, imaging findings, and treatment responses compared to Parkinson's disease[@tolosa2006].

Epidemiology

• Prevalence: 3-6% of all parkinsonism cases (approximately 0.5-1 per 100,000)
• Age of onset: Typically >65 years
• Sex ratio: Male predominance (1.5-2:1)
• Risk factors: Hypertension, diabetes, hyperlipidemia, smoking, prior stroke/transient ischemic attack[@reich2010]

Etiology and Pathophysiology

Vascular Lesions

VP results from ischemic or hemorrhagic lesions affecting multiple brain regions[@korczyn2015]:

| Region | Lesion Type | Clinical Impact |
|--------|-------------|-----------------|
| Basal ganglia (putamen, caudate, globus pallidus) | Lacunar infarcts, hemorrhage | Disrupted motor circuitry |
| Subcortical white matter | White matter hyperintensities | Impaired cortico-striatal connections |
| Thalamus | Strategic infarcts | Sensory and motor integration deficits |
| Brainstem (midbrain, pons) | Small vessel disease | Nigrostriatal damage |
| Substantia nigra | Rarely involved | Variable dopaminergic loss |

Pathophysiological Mechanisms

Direct neuronal damage: Ischemic injury to dopaminergic [neurons](/entities/neurons) in the substantia nigra pars compacta

Striatal disruption: Damage to striatal medium spiny neurons disrupting motor output

White matter injury: Lesions affecting cortico-striatal-pallidal-thalamic circuits

Small vessel disease: Chronic hypoperfusion and endothelial dysfunction

Multi-infarct state: Cumulative effect of multiple small strokes

Vascular Risk Factors

• Hypertension: Most significant risk factor
• Diabetes mellitus: Contributes to small vessel disease
• Hypercholesterolemia: Atherosclerosis
• Smoking: Endothelial damage
• Atrial fibrillation: Cardioembolic events
• Previous stroke: Direct vascular injury

Clinical Features

Core Motor Symptoms

• Bradykinesia: Prominent, often axial (trunk) > limbs
• Rigidity: Axial (neck and trunk) > limb, "lead-pipe" quality
• Gait difficulty: Early, prominent freezing of gait
• Postural instability: Frequent falls, often within first year

Distinctive Features Differentiating from PD

| Feature | Vascular Parkinsonism | Parkinson's Disease |
|---------|---------------------|-------------------|
| Onset | Symmetric | Often unilateral |
| Tremor | Minimal/restless | Classic resting tremor |
| Lower body | Prominent involvement | Less prominent |
| Progression | Stepwise | Gradual |
| Levodopa response | Poor to moderate | Good initially |
| Rigidity distribution | Axial > limbs | Limb > axial |

Additional Motor Features

• Lower body parkinsonism: Legs more affected than arms
• Gait freezing: Early and prominent
• Start hesitation: Difficulty initiating walking
• Festination: Short, shuffling steps
• Cortical sensory loss: Impaired position sense
• Pseudobulbar affect: Emotional lability

Non-Motor Features

Cognitive impairment:

• Executive dysfunction prominent
• Vascular dementia common
• Memory deficits
• Psychomotor slowing

Mood disorders:

• Depression (very common)
• Apathy
• Emotional lability

Autonomic dysfunction:

• Orthostatic hypotension
• Urinary incontinence (especially advanced)
• Constipation
• Sexual dysfunction

Other features:

• Dysphagia
• Dysarthria
• Sleep disorders (REM behavior disorder less common than in PD)

Diagnosis

Clinical Criteria

Proposed diagnostic criteria for VP:

Essential features:

• Parkinsonism (bradykinesia + ≥1 other sign: rigidity, tremor, postural instability)
• Evidence of cerebrovascular disease on neuroimaging
• Relationship between vascular lesions and parkinsonian features

Supportive features:

• Lower body parkinsonism
• Symmetric onset
• Poor levodopa response
• Early gait freezing
• Early cognitive impairment
• Presence of vascular risk factors

Exclusion criteria:

• History of idiopathic Parkinson's disease before stroke
• Other causes of parkinsonism (drug-induced, normal pressure hydrocephalus)
• Clinical features suggesting alternative diagnosis[@kalra2010]

Neuroimaging Findings

MRI Brain:

• White matter hyperintensities (Fazekas scale: grade 2-3)
• Lacunar infarcts in basal ganglia, thalamus, white matter
• Periventricular leukoaraiosis
• Old hemorrhagic lesions
• May show substantia nigra involvement

DaTscan (DaT-SPECT):

• Reduced dopamine transporter uptake in striatum
• Typically more symmetric than in PD
• Helps differentiate from essential tremor

CT Head:

• Periventricular hypodensities
• Basal ganglia calcifications
• Evidence of old infarcts

Differential Diagnosis

| Condition | Key Distinguishing Features |
|-----------|----------------------------|
| Idiopathic Parkinson's Disease | Unilateral onset, resting tremor, good levodopa response |
| Progressive Supranuclear Palsy | Vertical gaze palsy, early falls, axial rigidity |
| Multiple System Atrophy | Autonomic failure, cerebellar signs |
| Normal Pressure Hydrocephalus | Urinary incontinence, cognitive decline, gait apraxia |
| Drug-Induced Parkinsonism | Temporal relation to dopamine antagonists |

Treatment

Acute Vascular Event Management

• Secondary stroke prevention: Antiplatelets, anticoagulation if indicated
• Vascular risk factor control: Blood pressure, glucose, lipids
• Lifestyle modification: Smoking cessation, exercise

Antiparkinsonian Medications

Limited efficacy is characteristic of VP:

| Medication | Response | Notes |
|------------|----------|-------|
| Levodopa/Carbidopa | 30-40% | Often requires high doses; response incomplete |
| Dopamine agonists | Variable | May help some patients |
| MAO-B inhibitors | Limited | Selegiline, rasagiline |
| Amantadine | May help | May reduce freezing |
| Anticholinergics | Not recommended | Cognitive side effects |

Management of Non-Motor Symptoms

• Cognitive dysfunction: Acetylcholinesterase inhibitors (cautiously)
• Depression: SSRIs, SNRIs
• Orthostatic hypotension: Hydration, compression stockings, fludrocortisone
• Urinary incontinence: Anticholinergic medications, bladder training
• Falls: Physical therapy, balance training, home safety evaluation

Non-Pharmacological Approaches

Physical Therapy:

• Gait training
• Balance exercises
• Fall prevention
• Aquatic therapy

Occupational Therapy:

• Home safety assessment
• Assistive device training
• Energy conservation techniques

Speech Therapy:

• Dysarthria management
• Swallowing evaluation
• Communication strategies

Prognosis

Disease Course

• Progression: Stepwise rather than gradual, tied to new vascular events
• Functional decline: Often rapid following strokes
• Median survival: 5-9 years from diagnosis
• Cause of death: Stroke recurrence, pneumonia, falls

Prognostic Factors

Poor prognosis:

• Extensive white matter disease
• Multiple lacunar infarcts
• Early falls
• Poor levodopa response
• Rapid cognitive decline
• Recurrent strokes

Relatively better prognosis:

• Fewer vascular risk factors
• Controlled blood pressure
• Good rehabilitation
• Limited lesion burden

Research Directions

Emerging Therapies

• Vascular protection: Endothelial stabilizers
• Tissue plasminogen activator: Acute treatment considerations
• Neurogenesis: Stem cell approaches (experimental)
• [Tau](/proteins/tau)-focused treatments: Given overlap with tauopathies

Biomarker Development

• [Neurofilament light](/biomarkers/neurofilament-light-chain-nfl) chain: Disease burden marker
• Advanced MRI: Diffusion tensor imaging for white matter integrity
• PET imaging: Tau and amyloid imaging

Clinical Trials

• Focus on disease modification
• Neuroprotective strategies
• Targeted vascular therapies

See Also

• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)
• [Atypical Parkinsonism](/diseases/corticobasal-degeneration)
• [Cerebrovascular Disease](/mechanisms/cerebrovascular-disease)
• [White Matter Hyperintensities](/mechanisms/white-matter-disease)
• [Substantia Nigra](/brain-regions/substantia-nigra)
• [Basal Ganglia](/brain-regions/basal-ganglia)

External Links

• [National Institute of Neurological Disorders and Stroke](https://www.ninds.nih.gov/)
• [American Heart Association - Vascular Cognitive Impairment](https://www.heart.org/)
• [Parkinson's Foundation](https://www.parkinson.org/)

References

[Unknown, Critchley M. Arteriosclerotic parkinsonism. Brain. 1929;52(1):23-83 (1929)](https://doi.org/10.1093/brain/52.1.23)

[Zijlmans J, et al., Vascular parkinsonism--clinical features, neuroimaging, and differential diagnosis. Adv Neurol. 2003;91:383-391 (2003)](https://pubmed.ncbi.nlm.nih.gov/12414445/)

[Tolosa E, et al., The diagnosis of Parkinson's disease. Lancet Neurol. 2006;5(1):75-86 (2006)](https://doi.org/10.1016/S1474-4422(05)

[Unknown, Reich SG, Factor SA. Vascular parkinsonism. In: Parkinson's Disease. 2nd ed. Lippincott Williams & Wilkins; 2010 (2010)](https://pubmed.ncbi.nlm.nih.gov/21305724/)

[Unknown, Korczyn AD. Vascular parkinsonism--characteristics, pathogenesis and treatment. Nat Rev Neurol. 2015;11(6):319-326 (2015)](https://doi.org/10.1038/nrneurol.2015.61)

[Kalra S, et al., Diagnosis and management of vascular parkinsonism: an evidence-based review. Mov Disord. 2010;25(2):149-160 (2010)](https://doi.org/10.1002/mds.22887)